By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Stem Cell Research. According to news originating from Essen, Germany, by NewsRx correspondents, research stated, "Myelofibrosis is a myeloproliferative stem cell disorder curable exclusively by allogeneic hematopoietic stem cell transplantation and is associated with substantial mortality and morbidity. The aim of this study was to assess disease-specific and transplant-related risk factors that influence post-transplant outcome in patients with myelofibrosis."
Our news journalists obtained a quote from the research from University Hospital, "We retrospectively assessed 76 consecutive patients with primary (n=47) or secondary (n=29) myelofibrosis who underwent bone marrow (n=6) or peripheral blood stem cell (n=70) transplantation from sibling (n=30) or unrelated (n=46) donors between January 1994 and December 2010. The median follow-up of surviving patients was 55 ± 7.5 months. Primary graft failure occurred in 5% and the non-relapse mortality rate at 1 year was 28%. The relapse-free survival rate was 50% with a relapse rate of 19% at 5 years. The use of pharmacological pre-treatment and the post-transplant occurrence of chronic graft-versus-host disease were significant independent unfavourable risk factors for post-transplant survival in multivariate analysis. Using the Dynamic International Prognostic Scoring System for risk stratification, low-risk patients had significantly better overall survival (p=0.014, hazard ratio 1.4) and relapse-free survival (p=0.02, hazard ratio 1.3) compared to the other risk groups of patients. The additional inclusion of thrombocytopenia, abnormal karyotype and transfusion need (Dynamic International Prognostic Scoring System Plus) resulted in a predicted 5-year overall survival of 100%, 51%, 54% and 30% for low, intermediate-1, intermediate-2 and high-risk groups, respectively. The relapse incidence was significantly higher in the absence of chronic graft-versus-host disease (p=0.006), and pharmacological pre-treatment (n=43) was associated with reduced relapse-free survival (p=0.001). The data corroborate a strong correlation between alloreactivity and long-term post-transplant disease control and confirm an inverse relationship between disease stage, pharmacotherapy and outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis."
According to the news editors, the research concluded: "The Dynamic International Prognostic Scoring System was demonstrated to be useful for risk stratification of patients with myelofibrosis who are to undergo hematopoietic stem cell transplantation."
For more information on this research see: Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica, 2012;97(10):1574-81 (see also Stem Cell Research).
The news correspondents report that additional information may be obtained from M. Ditschkowski, Dept. of Bone Marrow Transplantation, WTZ, University Hospital of Essen, Essen, Germany. Additional authors for this research include A.H. Elmaagacli, R. Trenschel, T. Gromke, N.K. Steckel, M. Koldehoff and D.W Beelen.
Keywords for this news article include: Essen, Europe, Germany, Surgery, Treatment, Hematology, Myelofibrosis, Pharmacotherapy, Bone Marrow Cells, Stem Cell Research, Risk and Prevention, Cell Transplantation, Hematopoietic Stem Cells, Graft Versus Host Disease.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC